BACKGROUND Co-carbidopa was the first drug introduced for restless leg syndrome. But its use is not advocated much due to increased incidence of augmentation amongst the users. The first dopaminergic drug that was used in the treatment of RLS was co-carbidopa. However, it was noted in subsequent studies that there was a decline in the efficacy of co-carbidopa and there was an increase in the frequency, duration and intensity of symptoms with increased duration of co-carbidopa therapy which was

more »

... ermed as "augmentation". We wanted to define the role of co-carbidopa therapy in Chronic Restless Leg Syndrome and its association with augmentation. METHODS 30 patients of chronic RLS were selected according to the IRLSSG criteria. They were treated with co-carbidopa. Their IRLSSG scores were monitored at baseline, 2 months and 6 months. Every month, the patients were monitored according to Max Planck Institute criteria for development of augmentation. If the patients develop augmentation, they were treated with Gabapentin. The IRLSSG scores were compared for treatment efficacy.